Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial.
View Publication On PubMed
Export 
BiBTeXSEEK ID: https://cgnbonn.fdm.digital-medicine.org/publications/10
PubMed ID: 27540135
Trial Projects: Randomised phase III trial for previously untreated multiple myeloma to ...
Publication type: Journal
Journal: Haematologica
Citation: Haematologica. 2016 Dec;101(12):e485-e487. doi: 10.3324/haematol.2016.151266. Epub 2016 Aug 18.
Date Published: 20th Aug 2016
Registered Mode: by PubMed ID
Export PNG
Download
SubmitterViews: 140
Created: 5th Nov 2024 at 16:18
TagsThis item has not yet been tagged.
AttributionsNone
Related items
https://orcid.org/0000-0001-7712-224X
Trial Projects:
- Randomised phase III trial for previously untreated multiple myeloma to evaluate two regimens of bortezomib based induction therapy and lenalidomide consolidation followed by lenalidomide maintenance treatment
- A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)
- A non-interventional observational post authorization safety study of subjects treated with lenalidomide
- Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome and /or BCR-ABL Positive Chronic Myeloid Leucaemia in Chronic Phase (ENEST1st)
- Comparison between 5 – azacytidine treatment and 5 – azacytidine followed by allogeneic stem cell transplantation in elderly patients with MDS according to donor availability
Institutions: Klinik I für Innere Medizin, University Hospital Cologne
The main objectives of this trial are: 1.) Demonstration of non-inferiority of VCD induction therapy compared to PAd induction therapy with respect to response rate (very good partial remission or better; response criteria of the International Myeloma Working Group, IMWG).
2.) Determination of the best of four treatment strategies with respect to progression-free survival (PFS). The four treatment strategies are defined by PAd vs. VCD induction treatment, standard intensification therapy, ...
Public web page: Not specified
Start date: 1st Jun 2010
End date: 11th Mar 2017
